- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Patent holdings for IPC class C07D 417/14
Total number of patents in this class: 10437
10-year publication summary
|
646
|
715
|
695
|
741
|
711
|
719
|
871
|
785
|
709
|
507
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4764 |
295 |
| Merck Sharp & Dohme LLC | 3738 |
209 |
| Novartis AG | 10175 |
155 |
| Janssen Pharmaceutica N.V. | 3160 |
152 |
| Gilead Sciences, Inc. | 2242 |
147 |
| Takeda Pharmaceutical Company Limited | 2699 |
145 |
| Boehringer Ingelheim International GmbH | 4485 |
140 |
| F. Hoffmann-La Roche AG | 7800 |
133 |
| Amgen Inc. | 4436 |
124 |
| Hoffmann-La Roche Inc. | 3825 |
106 |
| Dana-Farber Cancer Institute, Inc. | 2669 |
92 |
| Merck Patent GmbH | 5739 |
90 |
| Syngenta Crop Protection AG | 6738 |
82 |
| LG Chem, Ltd. | 17956 |
74 |
| Cancer Research Technology Limited | 516 |
72 |
| Genentech, Inc. | 4119 |
71 |
| Abbvie Inc. | 1799 |
63 |
| Rigel Pharmaceuticals, Inc. | 520 |
62 |
| Shionogi & Co., Ltd. | 884 |
62 |
| Syngenta Participations AG | 1492 |
60 |
| Other owners | 8103 |